Fig. 8

T-MP-loaded monocytes can achieve therapeutic effects. a BALB/c mice (n = 6) were preinoculated with 3 × 10⁵ H22 hepatocarcinoma cells in the right rear thigh on day 0. Then monocytes, H22-MP-loaded monocytes or PBS were injected into the mice through tail vein on day 5. The tumor weight was measured on day 10. b Infiltrating lymphocytes from the above tumors were collected and the proportion of CD8⁺IFNγ⁺ T lymphocytes was measured via flow cytometry. c Similar setting as in a but C57BL/6 mice (n = 6) were preinoculated with 5 × 10⁵ B16-F10 melanoma cells and then vaccinated with monocytes, B16-MP-loaded monocytes or PBS through intravenous injection. d C57BL/6 mice (n = 5) were preinoculated with 1 × 10⁶ B16-OVA tumor cells through tail vein on day 0. After 5 days, OVA-MP-loaded monocytes or PBS were injected into the mice through tail vein three times, once every 5 days. On day 21, the B16-OVA tumor nodules in lungs were calculated. e Similar setting as in d and mice survival were analyzed (n = 8). f and g Similar setting as in d and the proportions of CD8⁺IFNγ⁺ T lymphocytes and SIINFEKL-specific CD8⁺ T lymphocytes in spleen of mice (n = 5) were measured by flow cytometry 21 days after B16-OVA tumor inoculation. h Similar setting as in d and splenocytes were isolated on day 21. Splenocytes were treated with irradiated B16-OVA cells, and used as effector cytotoxic T lymphocytes in tumor-specific cytotoxicity assay after 5 days. Mean ± s.e.m. is represented in the data. Log-rank test (e) or two-tailed unpaired Student's t test was used to statistically analyze the P values. ***P < 0.001; ****P < 0.0001; NS not significant